# Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

> **NCT05211336** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 14 (actual)

## Conditions studied

- Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)
- Aggressive B-cell Lymphoma With Secondary Involvement of the CNS

## Interventions

- **DRUG:** Obinutuzumab
- **DRUG:** Prednisone
- **DRUG:** Lenalidomide
- **DRUG:** Venetoclax
- **DRUG:** Ibrutinib
- **DRUG:** Acetaminophen
- **DRUG:** Diphenhydramine
- **OTHER:** Peg-filgrastim
- **DIAGNOSTIC_TEST:** CT Scan (chest, abdomen, and pelvis)
- **DIAGNOSTIC_TEST:** MRI
- **DIAGNOSTIC_TEST:** 18f-FDG-PET
- **DIAGNOSTIC_TEST:** PET
- **DIAGNOSTIC_TEST:** Lumbar puncture/Ommaya tap
- **DIAGNOSTIC_TEST:** Bone marrow aspiration/biopsy
- **COMBINATION_PRODUCT:** EKG

## Key facts

- **NCT ID:** NCT05211336
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-04-19
- **Primary completion:** 2024-06-01
- **Final completion:** 2029-06-01
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05211336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05211336, "Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05211336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*